NSNektarios Souvaliotis

Nektarios Souvaliotis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nektarios Souvaliotis has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vaccination Against SARS-CoV-2 Protects from COVID-19-induced Endothelial Dysfunction

    by Evangelos Oikonomou, Stamatios Lampsas, Nektarios Souvaliotis, Savvas Sarantos, Gerasimos Siasos, Garyphallia Poulakou, Thekla Lytra, Georgios Angelos Papamikroulis, Nikolaos Fountoulakis, Panagiotis Theofilis, et al.

    Background: Coronavirus Disease-19 (COVID-19) is implicated in endotheliitis which adversely affects cardiovascular events. The impact of vaccination with COVID-19 on the clinical outcome of patients is documented. Objective: To evaluate the impact of vaccination with COVID-19 on severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2) infection-related endothelial impairment. Methods: We enrolled 45 patients hospitalized for COVID-19 (either vaccinated or not against SARS-CoV-2). Clinical and laboratory data were collected, and brachial artery flow-mediated dilation (FMD) was evaluated. Subjects without COVID-19 were used as the control group. Results: There was no difference in age (64.7±7.5 years vs. 61.2±11.1 years vs. 62.4±9.5, p=0.28) and male sex (49% vs. 60% vs. 52%, p=0.71), between control subjects, vaccinated, and unvaccinated subjects with COVID-19 respectively. Of the patients with COVID-19, 44% were vaccinated against SARS-CoV-2. Unvaccinated COVID-19 patients had significantly impaired FMD compared to vaccinated COVID-19 patients and to Control subjects (2.05±2.41 % vs. 7.24±2.52 % vs. 7.36±2.94 %, p<0.001). Importantly, post hoc tests revealed that unvaccinated COVID-19 patients had significantly impaired FMD from both Vaccinated COVID-19 subjects (p<0.001) and form Control subjects (p<0.001). There was no difference in FMD between the control group and the vaccinated COVID-19 group (p=0.99). Conclusion: Hospitalized patients with COVID-19 present endothelial dysfunction in the acute phase of the disease. Endothelial function in unvaccinated patients with COVID-19 is impaired compared to control subjects as well compared to vaccinated patients with COVID-19. Vaccinated hospitalized subjects with COVID-19 do not show endothelial dysfunction, strengthening the protective role of vaccination against SARS-CoV-2.


  • Open Access

    The role of cardiometabolic risk factors and endothelial dysfunction in serum albumin levels and capillary leak syndrome of patients with COVID-19

    by E Oikonomou, S Lampsas, V Lampadiari, E Korakas, E Bletsa, N Souvaliotis, P Theofilis, A Tsatsaragkou, G Poulakou, D Tsoukalas, et al.

    Background: Growing evidence focuses on the role of hypoalbuminemia in the COVID-19 course and the role of vascular inflammation in the progression to Capillary Leak Syndrome (CLS). CLS may be mediated by a derangement of endothelial barrier following vascular endothelial dysfunction. We investigated the role of cardiometabolic risk factors in the association of hypoalbuminemia with endothelial dysfunction of hospitalized COVID-19 patients. Methods: In this cross-sectional study, patients hospitalized for COVID-19 at the medical ward or Intensive Care Unit (ICU) were enrolled. Medical history and laboratory examinations were collected while the endothelial function was assessed by brachial artery flow-mediated dilation (FMD) between the first 24–72 hours of their admission to the hospital. According to the body mass index, history of hypertension, dyslipidemia, and diabetes mellitus, COVID-19 patients were categorized in those with Cardiometabolic Risk Factors (CRFact) or without CRFact (no-CRFact). From the study population, we excluded subjects with established cardiovascular disease. Results: Sixty-six patients with COVID-19 (37% admitted in ICU) were recruited. From the study population, 41 were in the group of CRFact and 25 in the no-CRFact. Patients with CFRact were older (65±9 years vs. 53±14 years, p<0.001), had more impaired FMD (1.16±2.13% vs. 2.60±2.44%, p=0.01), and lower serum albumin levels (3.10±0.68 g/dL vs. 3.52±0.26 g/dL, p=0.006) compared to the no-CRFact group. Between CRFact and no-CRFact, there was no difference in CRP and IL-6 levels. Interestingly, serum albumin in patients with CRFact was significantly lower than the lower reference limit (LRL) (=3.5 g/dl) of albumin (p=0.001), while no such finding was noted in subjects with no CRFact (p=0.64). Furthermore, regression analysis revealed that, even after adjustment for age, the presence of CRFact was associated with decreased serum albumin levels by 0.31mg/dl (95% CI 0.08 to 0.63, p=0.04). In the CRFact population, there was a correlation of albumin with FMD (R=0.29, p=0.05) and an inverse correlation with CRP (rho=−0.48, p=0.02) and IL-6 (rho=−0.66, p<0.001), while in the no-CRFact group no such correlation were observed (p=NS for all). Conclusion: COVID-19 patients with cardiometabolic risk factors present with low serum albumin levels early at the course of the disease, which may be driven by endothelial dysfunction and vascular inflammation. This data gives insights into the potential association of a dysfunctional endothelial layer and the progression to capillary leak syndrome. Funding Acknowledgement: Type of funding sources: None.


  • Open Access

    Inside the “brain” of an artificial neural network: an interpretable deep learning approach to paroxysmal atrial fibrillation diagnosis from electrocardiogram signals during sinus rhythm

    by P Pantelidis, E Oikonomou, S Lampsas, N Souvaliotis, M Spartalis, M A Vavuranakis, M Bampa, P Papapetrou, G Siasos, M Vavuranakis

    Background: With the ongoing, rapid advances in Deep Learning (DL), such solutions can now detect medical conditions even invisible to the human eye. In this direction, efforts have been made to develop DL algorithms that diagnose paroxysmal atrial fibrillation (PAF) from electrocardiogram (ECG) signals in sinus rhythm (SR). However, many of the available approaches function as “black boxes”, with physicians unable to understand and trust their predictions. Purpose: To train a DL model to detect PAF patients while in SR and apply an algorithm that interprets and visualises its decisions. Methods: We obtained ECG samples from PAF and non-PAF patients during SR, from the PAF Prediction Challenge Database. After discarding unannotated samples and augmenting the sample size (by dividing each signal into 30-second segments), we split the whole dataset into a train (68%), a validation (16%) and a test (16%) set. No pair of samples belonging to different sets originated from the same patient. We trained the InceptionTime neural network on the train/validation sets and tested on the “unseen” test set after “hiding” the correct answers. Its performance was evaluated with the following metrics: Accuracy, f1-score, precision and recall (sensitivity). After repeating this process 20 times, we obtained a distribution for each score. Finally, we adjusted the Grad-CAM interpretation algorithm to our data and used it to visualise the areas perceived as important by the model. Results: After pre-processing, 4,080, 30-second, two-lead ECG signals were allocated to the train set, 960 to the validation and 960 to the test set. Each subset contained an equal number of PAF and non-PAF samples. After repeated training and testing, we obtained a median accuracy of 0.84 (interquartile range, IQR: 0.66–0.88), an f1-score of 0.82 (IQR: 0.68–0.88) and a median precision and recall equal to 0.93 (IQR: 0.67–0.99) and 0.77 (IQR: 0.68–0.93), respectively. The Grad-CAM technique highlighted the ECG areas of interest that led to each decision. We selected and present both PAF-positive and -negative samples, perceived either correctly or falsely. Interestingly, correct model decisions tend to focus on the P-wave, while false ones fixate on other regions. Conclusions: Although a pilot study with considerable limitations (small sample size, disregard of possible confounding due to comorbidities or other factors), this work shows how DL can be employed to distinguish between PAF and non-PAF patients from SR ECG samples, and confirms the potential of DL-enabled approaches to offer novel diagnostic capabilities. Most importantly, our effort provides a comprehensible, visual interpretation of the model's decisions. Demystifying DL behaviour can, not only improve such efforts by explaining false decisions, but also cultivate trust among clinicians and, possibly, point out directions for future research, since we can now see through the magnifying lens of a neural network. Funding Acknowledgement: Type of funding sources: None.


  • Open Access

    Short‐ and long‐term clinical predictors of pharmacological cardioversion of persistent atrial fibrillation by dofetilide: A retrospective cohort study of 160 patients

    by Hafeez Ul Hassan Virk, Waqas T. Qureshi, Nayani Makkar, Joseph Bastawrose, Nektarios Souvaliotis, Joshua Aziz, Emad Aziz

    Introduction: Dofetilide is a class III antiarrhythmic prescribed to cardiovert persistent atrial fibrillation (AF) to sinus rhythm (SR).Hypothesis: To determine the clinical predictors of cardioversion and readmission in persistent AF patients on dofetilide.Methods: We analyzed 160 patients with persistent AF who were started on dofetilide and followed for 1 year. We examined age, sex, race, hypertension, diabetes, smoking, dyslipidemia, CAD, left ventricular ejection fraction (LVEF), creatinine, BMI and concomitant use of calcium channel blockers (CCB), β‐blockers in a multivariable logistic regression model. We also examined the same predictors in Cox regression model for AF‐related readmission within 1 year of follow‐up.Results: 13.5% individuals did not convert to SR on dofetilide. 55.6% converted on the first dose and 83.1% converted by the fourth dose. In multivariable logistic models, dyslipidemia (OR: 2.4, CI: 1.12‐5.16) and LVEF (OR: 3.83,CI: 1.37‐10.8) were associated with failure to convert with the first dose. Female sex and LVEF also were associated with increased risk of failure to convert at all. Concomitant use of CCB associated with decreased risk of failure to convert to SR. In Cox proportional model, female sex, age <63 years and CAD were associated with increased AF readmission within 1 year.Conclusions: Dyslipidemia and LVEF <40% were associated with failure to cardiovert after first dose, and female sex and LVEF 40% were related to failure to convert at all on dofetilide in persistent AF patients. After 1‐year follow‐up, female sex, known CAD, and age <63 years were associated with increased AF readmissions.